Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Eukaryotic Gene Expression
Impact-faktor: 1.841 5-jähriger Impact-Faktor: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN Druckformat: 1045-4403
ISSN Online: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.v15.i2.50
pages 163-182

Nucleic Acid Modulation of Gene Expression: Approaches for Nucleic Acid Therapeutics Against Cancer

Yuji Nakata
Hematology/Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104
Tae-Kon Kim
Hematology/Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104
Susan Shetzline
Hematology/Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104
Alan M. Gewirtz
Hematology/Oncology, University of Pennsylvania School of Medicine

ABSTRAKT

Most cancers are characterized by abnormal gene expression, which is thought to contribute to the pathogenesis and maintenance of the malignant phenotype; abnormal proliferation, maturation, and apoptosis. Silencing such genes would appear to be a rational approach to the therapy of cancer, and some preliminary clinical studies support this concept. Of the strategies available, the anti-mRNA gene silencing approach has attracted much attention and is the focus of this review. This strategy includes three types of agents: (1) single-stranded antisense oligonucleotides; (2) catalytically active oligonucleotides, such as ribozymes, and DNAzymes that possess inherent RNA cleaving activity; and (3) small interfering RNA (siRNA) molecules that induce RNA interference (RNAi). Among these agents, antisense oligonucleotides, especially phosphorothioate (PS) oligonucleotides, have been the most frequently used in clinical trials. In this article, we provide an overview of anti-mRNA gene silencing agents and their development for use as cancer therapeutics.


Articles with similar content:

Gene Modulation for Treating Liver Fibrosis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 2
Kun Cheng, Ram I. Mahato
Polymeric Immunonanoparticles Mediated Cancer Therapy: Versatile Nanocarriers for Cell-Specific Cargo Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.35, 2018, issue 1
Niyati S. Acharya, Namdev L. Dhas, Ritu R. Kudarha, Sanjeev R. Acharya
Tumor Plasticity Interferes with Anti-Tumor Immunity
Critical Reviews™ in Immunology, Vol.34, 2014, issue 2
Andres Tittarelli, Salem Chouaib, Jean Paul Thiery, Bassam Janji, Alexander Eggermont
Kruppel-Like Factor 4: From Physiological Functions to Tumor Therapy
Forum on Immunopathological Diseases and Therapeutics, Vol.7, 2016, issue 1-2
Peng Li, Ruocong Zhao, Yunxin Lai
Tumor Hypoxia: A Key Determinant of Microenvironment Hostility and a Major Checkpoint during the Antitumor Response
Critical Reviews™ in Immunology, Vol.38, 2018, issue 6
Hussam H. Nawafleh, Stéphanie Buart, Rania Faouzi Zaarour, Stéphane Terry, Amirtharaj Francis, Prathibha Prasad, Nagwa Ahmed Zeinelabdin, Salem Chouaib, Goutham Hassan Venkatesh